Cargando…
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
Effective therapeutics to treat COVID-19 are urgently needed. While many investigational, approved, and repurposed drugs have been suggested, preclinical data from animal models can guide the search for effective treatments by ruling out treatments without in vivo efficacy. Remdesivir (GS-5734) is a...
Autores principales: | Williamson, Brandi N., Feldmann, Friederike, Schwarz, Benjamin, Meade-White, Kimberly, Porter, Danielle P., Schulz, Jonathan, van Doremalen, Neeltje, Leighton, Ian, Yinda, Claude Kwe, Pérez-Pérez, Lizzette, Okumura, Atsushi, Lovaglio, Jamie, Hanley, Patrick W., Saturday, Greg, Bosio, Catharine M., Anzick, Sarah, Barbian, Kent, Cihlar, Tomas, Martens, Craig, Scott, Dana P., Munster, Vincent J., de Wit, Emmie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486271/ https://www.ncbi.nlm.nih.gov/pubmed/32516797 http://dx.doi.org/10.1038/s41586-020-2423-5 |
Ejemplares similares
-
Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2020) -
Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021) -
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2
por: Williamson, Brandi N., et al.
Publicado: (2022) -
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022) -
SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)